TP53 and Miyoshi myopathy: In clinical practice, prognostication of MM using the revised International Staging System (R-ISS) [11] or the second revision of the International Staging System (R2-ISS) [12] is based solely on three high-risk cytogenetic abnormalities: t(4;14), t(14;16) and 17p/TP53 deletion for R-ISS and t(4;14), 17p/TP53 deletion and 1q21 gain/amplification for R2-ISS, in addition to biochemical markers including β2-microglobulin, serum lactate dehydrogenase and serum albumin.